KOL Perspectives: ABT-494 in Crohn’s disease
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
› Briefing includes analysis of KOL opinion on the following topic areas:
– Initial efficacy of ABT-494 in Crohn’s disease
– Safety of ABT-494
– Expected use of ABT-494 in Crohn’s disease based on Phase II data
– Ideal clinical trial comparators and future patient subpopulations
Scope
› The insight briefing is based on Sociable Pharma’s analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)
› In total, we conducted interviews with 10 KOLs:
– 5 Europe-based & 5 N. America-based
– Interviews performed during June 2017
> KOL data is analyzed to produce:
– Charts summarizing KOL opinions
– Chart call-outs of key information & details
– KOL quotes
– Summary of KOL reporting trends
– Insight from Sociable Pharma's analysts
Key Highlights
KOLs were broadly positive regarding ABT-494’s induction Phase II data in Crohn’s disease, with the use of endoscopic remission as a key endpoint boosting perceptions of efficacy in a tough, anti-TNF-IR population
ABT-494’s adverse event profile appears to reinforce physician perceptions of a class safety effect observed with JAK inhibitors
ABT-494monotherapy use is expected to be viewed as a positive characteristic, allowing for intermittent dosing, and reducing the potential for side effects associated (vs. combination with conventional immunosuppressants)
Reasons to Buy
Combines Qualitative & semi-quantitative insight from key opinion leaders on " ABT-494 in Crohn’s disease "
Includes insight & recommendations from our disease-specific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Crohn's disease
Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion
Pfizer
Gilead
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.